“Computational Repurposing of FDA-Approved Drugs Identifies Doxercalciferol and Timiperone as Potential Sirtuin 1 Inhibitors for Complex Diseases Therapy” (this title is in sentence case, which is a valid alternative to title case)

https://pubmed.ncbi.nlm.nih.gov/38117829

This study used computational methods to repurpose FDA-approved drugs and identified Doxercalciferol and Timiperone as potential Sirtuin 1 inhibitors, which could have implications for treating complex diseases like cancer, neurodegenerative disorders, and metabolic syndromes.